Ipca Laboratories Q1 FY27 Results (NSE: IPCALAB)
Signal: Margin expansion
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹2,788.1 Cr | +20.8% | +16.7% |
| Net profit | ₹401.89 Cr | +72.3% | |
| EPS | ₹15.84 | +72.4% | |
| EBIT margin | 22.88% |
P&L walk
Consolidated revenue rose to ₹2,788.10 crore, up 20.8% YoY and 16.7% QoQ, while EBITDA margin expanded to 22.88% from 18.39% and PAT attributable to owners increased 72.3% to ₹401.89 crore, helped by operating margin expansion and higher subsidiary contribution.
Research and educational content only. Not investment advice.